Investor Relations

Upcoming Event

Piper Sandler 32nd Annual Healthcare Conference

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Company Overview

Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company creating a broad variety of next-generation protein therapeutics for oncology based on its proprietary, cell-free protein synthesis platform, XpressCF.

Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.

Sutro designs cytokine-based immuno-oncology therapies, antibody-drug conjugates, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.

Sutro's platform allows it to accelerate discovery and development of first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.

Investor Contact Information

Company

Sutro Biopharma, Inc.
310 Utah Avenue
Suite 150
South San Francisco, CA 94080

Investor Relations

Sutro Biopharma
Annie J. Chang
Head of Investor Relations
T: 650-801-5728
ajchang@sutrobio.com

Media

Russo Partners
David Schull
T: (212) 845-4271
david.schull@russopartnersllc.com

Russo Partners
Maggie Beller
T: (646) 942-5631
maggie.beller@russopartnersllc.com